Arizona is currently home to 1662 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
NCT05266612
Recruiting
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors. All patients within a given dose level cohort will be treated with the same dose schedule of VG2025, administered as intratumoral injections at Day 1 and Day 15 biweekly at each treatment cycle (monotherapy cohorts 1-4 and combination cohort 1) and on day 1 and either day 2 or day 3 at the first 2 cycles followed by day 1 only at subsequent cycles (comb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Solid Tumor
Register for Updates
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
NCT05223816
Recruiting
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy Cohorts (Cohort 2 and 3) Cohort 2 (HCC) This part is a single-agent, single one-dose level and single-arm design. Approximately 39 subjects will be enrolled in the study to receive VG161. In the first stage, 21 subjects will be enrolled. If there is only 1 or fewer subjects has been observed with objective response and no more than 12 (\<13... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Mayo Clinic, Phoenix, Arizona
Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Register for Updates
Goal Setting to Promote Physical Activity Adherence in Midlife Adults
NCT05980052
Recruiting
Engaging in regular physical activity during midlife is a key lifestyle behavior associated with reduced risk for Alzheimer's disease and related dementias (AD/ADRD). Yet nearly half of midlife adults (48%) do not meet national physical activity guidelines. The purpose of this mechanistic trial is to identify effective goal setting techniques to enhance psychosocial processes of self-regulation for the successful promotion of PA and adherence to national PA guidelines among midlife adults, with... Read More
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
08/06/2024
Locations: Arizona State University, Phoenix, Arizona
Conditions: Physical Activity, Exercise
Register for Updates
Study of the Use of Orthopulse Photobiomodulation
NCT05650359
Recruiting
This PMCF study evaluates the safety and performance of OrthoPulse photobiomodulation to accelerate tooth movement during alignment with fixed appliances.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Private Practice, Chandler, Arizona
Conditions: Orthodontics
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Research Solutions of Arizona, PC, Litchfield Park, Arizona
Conditions: Ulcerative Colitis
Register for Updates
A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production
NCT04558541
Recruiting
The broad aim of this clinical study is to assess the hypothesis that morphological and phonological deficits are linked by a broader deficit in sequential pattern learning. This hypothesis applies to learning in general, but is especially critical as an avenue for developing earlier assessments and more powerful interventions for children with developmental language disorder (DLD; also known as specific language impairment). Other populations, such as at-risk toddlers, may also benefit from thi... Read More
Gender:
ALL
Ages:
Between 4 years and 8 years
Trial Updated:
08/06/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Register for Updates
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/05/2024
Locations: Site 4058, Tucson, Arizona
Conditions: Major Depressive Disorder, Anhedonia
Register for Updates
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
NCT05877053
Recruiting
The purposes of this study are to: * Learn about the safety and tolerability of CK 4021586 after a single dose and multiple doses in healthy subjects. * Find out how much CK-4021586 is in the blood after a single dose and multiple doses. * Determine the effect different doses of CK-4021586 on the pumping function of the heart. * Determine the effect of food in the stomach on how much CK-4021586 is in the blood after a single dose.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/05/2024
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction
NCT05860257
Recruiting
Adolescence is a developmental period of significant risk for anxiety, depressive symptoms, and suicidality, and the investigators propose to target key peer-based risk and protective factors using Cooperative Learning (CL). CL is a small-group instructional approach that can enhance peer relations and reduce peer-related risks, as well as promote academic engagement and achievement and reduce racial disparities. CL will be delivered with the aid of technology that automates the design and deliv... Read More
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
08/05/2024
Locations: Arizona State University, Tempe, Arizona
Conditions: Anxiety Depression, Suicidal Ideation
Register for Updates
SMLI With Hispanic Cancer Survivors and Caregivers
NCT05364372
Recruiting
Fewer than 20% of Hispanic cancer survivors meet the American Cancer Society's (ACS) Guidelines on Nutrition and Physical Activity. Diagnosed at younger ages, later stages and with fewer resources (e.g., access to care), Hispanic cancer survivors are more likely to suffer from many symptoms, which linger long after they have completed treatment and may prevent them from leading a healthy life. Healthier lifestyle behaviors (such as diet and physical activity) would result in an immediate benefit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Cancer Survivors, Cancer
Register for Updates
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
NCT02022943
Recruiting
The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enrolled individuals will receive regular email communications. As research studies become available, individuals will be notified via email with information as to how proceed should they be interested. Regi... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
08/05/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona
Conditions: Alzheimer's Disease, Dementia
Register for Updates